Martek Limited

Martek Biosciences Corporation

Advanced Bionutrition Corporation

Carnegie Institution of Washington

Advanced Bionutrtion Corporation

David J Kyle

F C Thomas Allnutt

Sue E Reeb

Valerie J Sicotte

Kirk Emil Apt

Raymond M Gladue

Ruth Barratt

Robert Bullis

James Casey Lippmeier

Moti Harel

John Piechocki

Arthur R Grossman

James Casy Lippmeier

Kirk R Apt

F C Allnutt

Carotenoids are provided as dietary supplements to animal feed. These supplements improve the bioavailability of carotenoids by providing them in combination with phospholipids. The invention provides animal feeds for aquatic and terrestrial animals, and methods for making the feeds.

Absorption of fat-soluble nutrients

A microbial biomass, made from algae, bacteria, fungi, yeast, or combinations thereof, provides a feed for animals raised either in agriculture or aquaculture. A feed additive, and a therapeutic composition can also be made from a microbial biomass of algae, bacteria, fungi, yeast, or combinations thereof. The feed, feed additive, and therapeutic composition can comprise one or more proteins, peptides, antibodies, antibody fragments, or a combination thereof, wherein said proteins, peptides, antibodies, antibody fragments, or a combination thereof are non-native to the microbes of the biomass. The biomass can have therapeutic, bioactive, nutritional, and/or immunogenic properties.

Delivery of disease control in aquaculture and agriculture using microbes containing bioactive proteins

Most microalgae are obligate photoautotrophs and their growth is strictly dependent on the generation of photosynthetically-derived energy. In this study it is shown that the microalgacan be engineered to import glucose and grow in the dark through the introduction of genes encoding glucose transporters. Both the human andglucose transporters facilitated the uptake of glucose by, allowing the cells to metabolize exogenous organic carbon and thrive, independent of light. This is the first successful trophic conversion of an obligate photoautotroph through metabolic engineering, and it demonstrates that methods of cell nourishment can be fundamentally altered with the introduction of a single gene. Since strains transformed with the glucose transport genes are able to grow non-photosynthetically, they can be exploited for the analysis of photosynthetic processes through mutant generation and characterization. Finally, this work also represents critical progress toward large-scale commercial exploitation of obligate phototrophic algae through the use of microbial fermentation technology, eliminating significant limitations resulting from light-dependent growth.

Trophic conversion of obligate phototrophic algae through metabolic engineering

A crustacean or rotifer is infected with a recombinant infectious virus that expresses a protein exogenous to the virus. The genome of the crustacean or rotifer itself remains unaltered. Crustacean, rotifer, insect, or viral promoters drive the transcription of a gene inserted into the recombinant virus genome, and the virus replicates in the crustacean or rotifer cell cytoplasm. The infected crustacean or rotifer can be provided directly to humans or non-human animals, or, following production and harvest of the crustaceans or rotifers, purified recombinant protein or polypeptide can be provided. Large quantities of biopharmaceuticals can be produced rapidly and inexpensively using this production system.

Crustaceans as production systems for therapeutic proteins

Transfected shrimp as production systems for therapeutic proteins

An animal feed with a high level of arachidonic acid is produced from microalgae, and fed to aquatic animals grown in aquaculture. The arachidonic acid-rich microalgae are fed directly to the aquatic animals, or processed to produce an oil that can be used as a human nutritive supplement. The arachidonic acid-rich microalgae can be combined with long chain omega-3 fatty acids to provide a source of nutrition for humans and animals. The animal feed and nutritional supplements are free of animal byproducts.

Microalgal feeds containing arachidonic acid and their production and use

Methods and tools for transformation of eukaryotic algae

A biomass is provided which consists essentially of cells of dinoflagellates of the class Dinophyceae which have been cultivated to produce high cell mass and high DHA content. Biomass consisting of cells of Crypthecodinium cohnii is preferred. The cells are cultivated in an aerobic fermentor to achieve a cell density of a least 10 grams biomass per liter of nutrient solution by maintaining in the fermentor a dissolved oxygen level of at least about 10% of air saturation, and by inducing a stationary phase with a limiting nitrogen source in the nutrient solution. Under these conditions a single cell oil which contains at least 20% docosahexaenoic acid (DHA) in the triglyceride form at a concentration of at least about 1.5 grams per liter of nutrient solution is produced in the biomass. The biomass is suitable as an aquaculture feed.

Dinoflagellate biomass, methods for its production, and compositions

The present invention relates to processes for the production of arachidonic acid containing oils, which preferably are substantially free of eicosapentaneoic acid. The invention also relates to compositions containing such oils, in an unmodified form, and to uses of such oils. In a preferred embodiment, Pythium insidiosum is cultivated, harvested and the oil is extracted, recovered, and used as an additive for infant formula. In an alternative embodiment, Mortierella alpina is cultivated, harvested and the oil is extracted, recovered, and used as an additive for infant formula.

Arachidonic acid and methods for the production and use thereof

Eicosapentaenoic acid-containing oil and methods for its production

The present invention relates to compositions including blends of microbial oils, methods of using such compositions, particularly as supplements for infant formula, and methods of increasing the amount of long chain polyunsaturated fatty acids in infant formula.

Microbial oil mixtures and uses thereof

A pharmaceutical composition and a dietary supplement comprising a single cell oil containing at least 20% docosahexaenoic acid (DHA) in triglyceride form are presented. The single cell oil is extracted from biomass produced by cultivating heterotrophic microalgae of the class Dinophyceae in an aerobic fermentor with a nutrient solution having a limited nitrogen source.

Pharmaceutical composition and dietary supplement containing

Labelled triglyceride oils are produced for use in diagnostic breath test. The process involves the cultivation of microorganisms capable of producing the oils in an appropriately controlled environment wherein the microorganisms are fed .sup.13 C or .sup.14 C labeled carbon substrates to induce the microorganisms to produce the labeled oils. The preferred labelled carbon substrate is a substrate containing .sup.13 C. The oil produced is preferrably enriched in oleic acid. The microorganisms can be induced to produce the oil by nitrogen depletion during cultivation.

Method of diagnosing fatty acid metabolism or absorption disorders using

This invention relates to a process for producing a single cell edible oil containing DHA, to the oil itself and to uses for the oil. Marine microorganisms are cultivated in fermentors and induced to produce the single cell oil which subsequently is recovered by extraction with solvents.

Growing community of inventors

Catonsville, MD, United States of America

David J Kyle